Latest news with #AstraZenecaPharma
Business Upturn
a day ago
- Business
- Business Upturn
AstraZeneca Pharma shares in focus as global parent reports Q2 results
AstraZeneca Pharma shares were in focus on Tuesday after its global parent reported better-than-expected results for the second quarter of 2025, driven by strong performance in its oncology portfolio. For Q2, AstraZeneca reported revenue of $14.46 billion, ahead of the $14.12 billion estimate. Core earnings per share stood at $2.17, in line with projections, and the core operating margin remained steady at 32%. One of the key highlights was Imfinzi, a major cancer drug, which clocked $1.46 billion in revenue, surpassing expectations of $1.34 billion. The company declared an interim dividend of $1.03 per share and reiterated its full-year 2025 guidance, expecting high single-digit percentage growth in total revenue and low double-digit growth in core EPS. AstraZeneca Pharma shares traded in a narrow range on July 29, moving between ₹8,865.50 and ₹9,000.00 during the session. The stock opened at ₹8,944.50, slightly above its previous close of ₹8,937.50. Despite the subdued movement, the stock remains significantly above its 52-week low of ₹6,220.00, though still below the 52-week high of ₹10,691.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
&w=3840&q=100)
Business Standard
18-07-2025
- Business
- Business Standard
Here's why AstraZeneca Pharma share price is down over 2% today
AstraZeneca Pharma share price: Shares of pharma major AstraZeneca Pharma India dropped 2.5 per cent to ₹9,165 per share during intraday deals on Friday and continued to trade lower. At around 2:20 PM, they were trading at approximately ₹9,165 per share, down 2.10 per cent from their previous close of ₹9,394 on the NSE. A combined nearly 0.17 lakh equity shares of AstraZeneca Pharma, estimated to be worth around ₹16 crore, changed hands on the BSE and NSE. Here's why AstraZeneca Pharma's share price declined today The decline in the company's share price came as the company's shares traded ex-date following its announcement of dividend rewards of ₹32 per share for the financial year 2024–25 (FY25). Notably, the ex-dividend date marks the day a stock begins trading without the value of its declared dividend. To be eligible for the dividend, investors must own the stock before the ex-dividend date. AstraZeneca Pharma dividend record date AstraZeneca Pharma dividend history The company has a strong history of awarding dividends. According to NSE data, it paid ₹8 per share in 2022, ₹16 per share in 2023, and ₹24 per share in 2024 to its shareholders. AstraZeneca Pharma dividend yield At the current market price, AstraZeneca Pharma has a dividend yield of 0.35 per cent. About AstraZeneca Pharma AstraZeneca Pharma, a subsidiary of AstraZeneca Plc (UK), is engaged in the manufacture, distribution, and marketing of pharmaceutical products, and coordinates clinical trial services with its overseas group company. The company operates across major therapeutic areas including oncology, alimentary & metabolism, cardiovascular, renal diabetes, respiratory, infections, neuroscience, and inflammation. As of July 18, the pharma major boasts a market capitalisation of ₹22,912.50 crore on the NSE. AstraZeneca Pharma share price history AstraZeneca Pharma's share price has appreciated 42 per cent year-to-date, compared to a 5 per cent gain in the benchmark Nifty50 during the same period. The shares scaled a 52-week high of ₹10,691 on June 13, 2025, and hit a 52-week low of ₹6,220 on November 21, 2024, on the NSE.
Business Upturn
15-07-2025
- Business
- Business Upturn
Astrazeneca Pharma shares jump 3% after company gets CDSCO approval for import, sale of bladder cancer drug
By Aman Shukla Published on July 15, 2025, 09:47 IST AstraZeneca Pharma shares surged 3% today after the company received a key regulatory nod from India's Central Drugs Standard Control Organisation (CDSCO). The approval allows AstraZeneca to import and sell its cancer drug Durvalumab (branded as Imfinzi) in India for an additional use. This new approval covers two dosage forms—120 mg/2.4 ml and 500 mg/10 ml—and expands Imfinzi's indication to treat adult patients with muscle invasive bladder cancer (MIBC). Specifically, the drug can now be used in combination with gemcitabine and cisplatin as a neoadjuvant (pre-surgery) treatment. After surgery (radical cystectomy), Imfinzi can continue as a standalone adjuvant (post-surgery) therapy. The expanded label marks a significant milestone for AstraZeneca in India's oncology market, particularly in bladder cancer treatment. The company can now begin marketing Imfinzi for this new use, subject to any further clearances that may be needed. Imfinzi is already approved globally for other cancer indications, including lung and biliary tract cancers. This latest CDSCO approval adds another layer to its growing clinical footprint in India. AstraZeneca Pharma shares opened at ₹9,195.00 and touched a high of ₹9,650.50 during the day. The stock did not fall below its opening price, marking ₹9,195.00 as the low. Over the past year, the stock has seen a 52-week high of ₹10,691.00 and a low of ₹6,220.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
&w=3840&q=100)
Business Standard
02-07-2025
- Business
- Business Standard
AstraZeneca Pharma pops 4% on CDSCO nod to import Durvalumab solution
AstraZeneca Pharma share price: Pharmaceutical company AstraZeneca Pharma share price was buzzing in trade on Wednesday, July 2, 2025, with the stock rising up to 3.83 per cent to an intraday high of ₹9,239.25 per share. At 12:31 PM, AstraZeneca Pharma share price continued to trade near day's high levels, up 3.28 per cent at ₹9,190. In comparison, BSE Sensex was trading 0.19 per cent lower at 83,535.28 levels. What triggered the up move in AstraZeneca Pharma share price? AstraZeneca Pharma shares rose after the company received regulatory approval to expand the use of its cancer drug Imfinzi (Durvalumab) in India. The Central Drugs Standard Control Organisation (CDSCO) granted permission to import and distribute Durvalumab Solution for Infusion (120 mg/2.4 ml and 500 mg/10 ml) for an additional indication. In an exchange filing, AstraZeneca Pharma said, 'This is to inform that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml (Brand name: Imfinzi) for an additional indication.' The new approval allows Durvalumab, in combination with carboplatin and paclitaxel, to be used as a first-line treatment for adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This is followed by maintenance treatment with Durvalumab and olaparib in cases of mismatch repair proficient (pMMR) endometrial cancer. The development enables AstraZeneca Pharma to market the drug in India for the newly approved indication, subject to further statutory approvals, if required. Track Stock Market LIVE Updates About AstraZeneca Pharma AstraZeneca Pharma is a British-Swedish multinational pharmaceutical and biotechnology company, formed in 1999 through the merger of Sweden's Astra AB and Britain's Zeneca Group. The company is dedicated to developing and selling innovative medicines across various therapeutic areas, including cancer, cardiovascular diseases, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation. The company has had a major presence in India for 45 years. AstraZeneca Pharma India oversees manufacturing, sales, and marketing operations, while the company also gained global recognition for its role in developing the Oxford–AstraZeneca Covid-19 vaccine Leveraging data science and artificial intelligence (AI), AstraZeneca claims to boost the success rates and efficiency of its research and development (R&D) processes. The market capitalisation of AstraZeneca Pharma is ₹22,988.75 crore, according to BSE. The company falls under the BSE500 index. The 52-week high of AstraZeneca share price is ₹10,653.05, while its 52-week low is ₹6,222.35.
&w=3840&q=100)
Business Standard
02-06-2025
- Business
- Business Standard
AstraZeneca Pharma shares surge 12% after Q4 results; profit jumps 48%
Shares of AstraZeneca Pharma India rallied nearly 12 per cent on Monday after its net profit for the fourth quarter of the previous financial year (Q4 FY25) jumped 48 per cent to ₹58.25 crore year-on-year (Y-o-Y). The pharma major's stock rose as much as 11.87 per cent during the day to ₹8,919 per share, the biggest intraday gain since March 20 this year. The stock pared gains to trade 11.2 per cent higher at ₹8,875 apiece, compared to a 0.54 per cent decline in Nifty50 as of 10:54 AM. Shares of the company extended gains to their third day while they have fallen 21 per cent this year, compared to a 4.1 per cent advance in the benchmark Nifty50. AstraZeneca Pharma has a total market capitalisation of ₹22,195.5 crore, according to BSE data. Track LIVE Stock Market Updates Here AstraZeneca Pharma Q4 results The pharma major reported a 48 per cent rise in consolidated net profit for Q4 FY24 to ₹58.25 crore. Total revenue from operations stood at ₹480.48 crore, up 25.3 per cent Y-o-Y. The company also recorded significant growth across therapeutic areas, achieving a 32 per cent increase in full-year revenue compared to the previous year. In its oncology business, the pharma major reported revenue of ₹315.85 crore in Q4FY25, a rise of 31.62 per cent. Additionally, revenue from biopharmaceuticals (cardiovascular, renal and metabolism; respiratory and immunology; and vaccines and immune therapies) rose 1.9 per cent to ₹122.74 crore. The rare disease segment grew to Rs 2 crore in Q4FY25, up from Rs 0.17 crore in Q4FY24. AstraZeneca Pharma management commentary 'FY2024–25 marked significant progress for AstraZeneca Pharma India Limited, driven by strong growth of 32 per cent," said Bhavana Agrawal, Chief Financial Officer and Director, AstraZeneca Pharma. "This reflects our strategic focus on science, specialists, and the strength of our innovation-led portfolio. As we scale impact across therapy areas, we remain committed to delivering sustainable value to the people, society, and the planet.' About AstraZeneca Pharma AstraZeneca Pharma is a British-Swedish multinational pharmaceutical and biotechnology company, formed in 1999 through the merger of Sweden's Astra AB and Britain's Zeneca Group. The company is dedicated to developing and selling innovative medicines across various therapeutic areas, including cancer, cardiovascular diseases, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation. The company has had a major presence in India for 45 years. AstraZeneca Pharma India oversees manufacturing, sales, and marketing operations, while the company also gained global recognition for its role in developing the Oxford–AstraZeneca Covid–19 vaccine
